3. Ongoing trials: actively recruiting or completed; not yet published.

Trial registration number; trial registry	Location(s)	Interventions; abbreviated name	Recruitment status	Estimated completion	Target enrolment
NCT04600999 ClinicalTrials.gov	Hungary	FVP versus standard of care	Recruiting	June 2021	150
NCT04613271 ClinicalTrials.gov	Indonesia	FVP versus azithromycin	Recruiting	December 30, 2021	210
NCT05041907 ClinicalTrials.gov	Brazil Thailand	FVP versus standard of care	Recruiting	August 2024	1500
NCT05014373 ClinicalTrials.gov	Philippines	Favipiravir + best standard of care versus standard of care	Recruiting	August 31, 2021	144
NCT04445467 ClinicalTrials.gov	Australia	FVP versus placebo	Active, not recruiting	December 2021	190
NCT05279235 ClinicalTrials.gov	China Uzbekistan	FVP versus placebo	Not yet recruiting	July 2022	640
U1111‐1274‐5868 REBEC	Brazil	FVP versus placebo	Not yet recruiting	March 2023	402
NCT04359615 ClinicalTrials.gov	Iran	FVP + hydroxychloroquine versus hydroxychloroquine	Active, not recruiting	May 2020	40
NCT04425460 ClinicalTrials.gov	China Germany Romania	FVP versus placebo	Active, not recruiting	September 2020	256
jRCT2041210004 JCRCT	Japan	FVP versus placebo	Not recruiting	April 2022	316
TCTR20200514001 Thai Clinical Trial Registry	Thailand	FVP versus standard of care	Complete	28 February 2022	96
NCT04310228 ClinicalTrials.gov	China	Favipiravir versus favipiravir + tocilizumab versus tocilizumab	Unknown	May 2020	150
NCT04501783 ClinicalTrials.gov	Russia	FVP versus standard of care	Active, not recruiting	August 2020	168
ISRCTN31062548 ISTRCN registry	UK, Scotland	FVP versus standard of care	Active, recruiting	July 2022	302
NCT04319900 ClinicalTrials.gov	China	Chloroquine + FVP versus FVP versus placebo	Unknown	June 2020	150
NCT04558463 ClinicalTrials.gov	Indonesia	FVP versus oseltamivir	Unknown	October 2020	100
EUCTR2020‐001435‐27‐FR	France	Telmisartan versus hydroxychloroquine versus FVP versus imatinib versus placebo	Completed	October 2021	845
IRCT20211004052664N1 Iranian Registry of clinical trials	Iran	FVP versus standard of care	Completed	December 2021	80

FVP: favipiravir